DTC
Deep Track Capital Portfolio holdings
AUM
$3.11B
This Quarter Return
+23.38%
1 Year Return
+13.6%
3 Year Return
+265.73%
5 Year Return
–
10 Year Return
–
AUM
$3.48B
AUM Growth
+$3.48B
(+22%)
Cap. Flow
+$477M
Cap. Flow
% of AUM
13.71%
Top 10 Holdings %
Top 10 Hldgs %
38.49%
Holding
77
New
19
Increased
14
Reduced
16
Closed
11
Top Buys
| 1 |
Amgen
AMGN
|
$156M |
| 2 |
Alnylam Pharmaceuticals
ALNY
|
$124M |
| 3 |
Dyne Therapeutics
DYN
|
$72.5M |
| 4 |
MindMed
MNMD
|
$62.7M |
| 5 |
Apellis Pharmaceuticals
APLS
|
$58.8M |
Top Sells
| 1 |
AMAM
Ambrx Biopharma, Inc. Common Stock
AMAM
|
$52.8M |
| 2 |
Sarepta Therapeutics
SRPT
|
$48.2M |
| 3 |
RAPT Therapeutics
RAPT
|
$44.6M |
| 4 |
Arcellx
ACLX
|
$40.2M |
| 5 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$34.6M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
AnaptysBio
ANAB
$630M
| $11.9M | 0.34% |
529,452
-1,507,538
| -74% | -$33.9M |
|
|
RGLS
52
DELISTED
Regulus Therapeutics
RGLS
| $9.41M | 0.27% |
+3,266,566
| New | +$9.41M |
|
53
Alto Neuroscience
ANRO
$97.7M
| $9.21M | 0.26% |
+600,000
| New | +$9.21M |
|
54
Ultragenyx Pharmaceutical
RARE
$3.04B
| $7.83M | 0.22% |
+167,784
| New | +$7.83M |
|
55
Zura Bio
ZURA
$132M
| $6.48M | 0.19% |
2,523,000
| – | – |
|
|
ALLK
56
DELISTED
Allakos
ALLK
| $6.3M | 0.18% |
5,000,000
+2,489,264
| +99% | +$3.14M |
|
57
Aligos Therapeutics
ALGS
$75.1M
| $5.98M | 0.17% |
244,111
| – | – |
|
58
Relmada Therapeutics
RLMD
$48.8M
| $5.77M | 0.17% |
1,240,034
-804,473
| -39% | -$3.74M |
|
|
VIGL
59
DELISTED
Vigil Neuroscience
VIGL
| $5.44M | 0.16% |
1,594,931
| – | – |
|
60
Metagenomi
MGX
$67.2M
| $4.92M | 0.14% |
+466,232
| New | +$4.92M |
|
|
SYRS
61
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $4.43M | 0.13% |
828,485
| – | – |
|
62
Mersana Therapeutics
MRSN
$34.8M
| $2.6M | 0.07% |
+23,187
| New | +$2.6M |
|
63
Prime Medicine
PRME
$595M
| $2.13M | 0.06% |
+303,716
| New | +$2.13M |
|
64
Cogent Biosciences
COGT
$1.83B
| $2.12M | 0.06% |
+316,000
| New | +$2.12M |
|
65
Structure Therapeutics
GPCR
$1.14B
| $1.72M | 0.05% |
40,137
-259,863
| -87% | -$11.1M |
|
|
66
Sarepta Therapeutics
SRPT
$1.98B
| – | – |
-500,000
| Closed | -$48.2M |
|
|
AMAM
67
DELISTED
Ambrx Biopharma, Inc. Common Stock
AMAM
| – | – |
-3,710,412
| Closed | -$52.8M |
|
|
68
Arcellx
ACLX
$3.95B
| – | – |
-725,145
| Closed | -$40.2M |
|
69
Agios Pharmaceuticals
AGIO
$2.36B
| – | – |
-1,062,881
| Closed | -$23.7M |
|
70
Cytokinetics
CYTK
$5.98B
| – | – |
-288,949
| Closed | -$24.1M |
|
71
Edgewise Therapeutics
EWTX
$1.54B
| – | – |
-2,537,176
| Closed | -$27.8M |
|
72
GH Research
GHRS
$870M
| – | – |
-499,400
| Closed | -$2.9M |
|
73
Jazz Pharmaceuticals
JAZZ
$7.99B
| – | – |
-48,280
| Closed | -$5.94M |
|
74
Prothena Corp
PRTA
$452M
| – | – |
0
| – | – |
|
75
Protagonist Therapeutics
PTGX
$3.62B
| – | – |
-275,201
| Closed | -$6.31M |
|